Loading
The Taiwanese study behind OneTest's algorithm: in 27,938 people having routine tumour-marker check-ups, a machine-learning score separated those later diagnosed with cancer only moderately well.
Wang and colleagues (Chang Gung Memorial Hospital, Linkou, Taiwan, with 20/20 GeneSystems) developed sex-specific cancer screening algorithms and an organ-of-origin algorithm from tumour-marker values, age and sex of 27,938 asymptomatic people screened at a Taiwanese medical centre between May 2001 and April 2015, 342 of whom were later confirmed to have cancer, with external validation at a second centre. The area under the curve was 0.8736 for men and 0.6938 for women in external cross validation. The organ-system algorithm had 81.2% sensitivity and 64.9% specificity for men and 81.7% and 67.5% for women. The authors' disclosure states that 20/20 GeneSystems is commercialising the algorithms under the OneTest brand.
An area under the curve of 0.69 for women is weak discrimination; the paper reports risk groups rather than a positive predictive value, so it does not show how many positive OneTest results are cancer.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/